Clinical Trial Update: Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6 [Phase 4]

View source ↗

Summary

Phase 4 trial comparing fixed-dose combination sofosbuvir/ledipasvir for 8 vs 12 weeks in chronic hepatitis C genotype 6; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Ledipasvir (sofosbuvir/ledipasvir)

Snippet

Sponsor: Stanford University | Conditions: PT-NANBH | Phase 4 | Status: COMPLETED | Results posted: 2017-09-19